Communiqués Imunon, Inc.

Actions

IMNN

US15117N7012

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 06/10/2026			Varia. 5j.	Varia. 1 janv.
1,120 ^USD	-9,68%		-18,84%	-70,60%

24/09	IMUNON, Inc. présente une mise à jour de son programme de développement d’IMNN-001 pour les femmes atteintes d’un cancer de l’ovaire avancé nouvellement diagnostiqué	CI
23/09	Transcript : Imunon, Inc. - Shareholder/Analyst Call

Communiqués

29/09	IMUNON Converts $1.2 Million of Debt-to-Equity	AQ
24/09	IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan	AQ
22/09	IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review	AQ
10/09	IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001	AQ
09/09	IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress	AQ
26/08	IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001	AQ
11/08	IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update	AQ
04/08	IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026	AQ
30/07	IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer	AQ
23/07	IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development	AQ
21/07	IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer	AQ
23/06	IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification	AQ
22/06	IMUNON to Present at the Life Sciences Investor Forum on June 25th	AQ
04/06	IMUNON Announces Up to $10 Million Cash Financing	AQ
12/05	IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
05/05	IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026	AQ
31/03	IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study	AQ
25/03	IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer	AQ
24/03	IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026	AQ
05/02	IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY	AQ
30/12	IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules	AQ
29/12	IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026	AQ
13/11	IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
10/11	IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer	AQ
10/11	IMUNON : R&D Day Highlighting Progress on OVATION 3 Study	PU